Loading
institutionsInstitution
Cancer Institute of Iran, Imam Khomeini Hospital Complex
Iran's oldest and largest cancer centre, founded in 1955 within Tehran's Imam Khomeini Hospital Complex, and the country's main oncology training and research hub.
Also called: Tehran Cancer InstituteCancer Research Center, Tehran University of Medical Sciencesانستیتو کانسر
Overview
The Cancer Institute of Iran was established in 1955 as part of the Imam Khomeini Hospital Complex of Tehran University of Medical Sciences and is the largest cancer hospital in Iran, offering surgical, medical and radiation oncology, breast and gastrointestinal cancer surgery, nuclear medicine and a Cancer Research Center that runs the Tehran cancer registry and epidemiological studies. TUMS investigators contribute to the Golestan Cohort Study of oesophageal cancer in north-eastern Iran, one of the most important cohorts in the Middle East and a long-running collaboration with IARC and the US National Cancer Institute, and to research on gastric cancer, breast cancer in younger women and the effects of sanctions on drug access. The institute trains most of Iran's oncology specialists.
Location
Tehran, IR
Type
cancer center · Tehran University of Medical Sciences
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#326 · 20 points (0 Newsweek + 0 NCI + 20 from 10 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to Imam Khomeini Hospital, including child institutions. 176 works · 1,774 citations · 83% open access · 4% clinical trials · 8% reviews.
Oncology works per year
312022
382023
492024
402025
182026
Most works
- Reza Ghalehtaki12 works
- Behnam Behboudi10 works
- Mahdi Aghili9 works
- Alireza Kazemeini8 works
- Seyed Mohsen Ahmadi Tafti7 works
- Ramesh Omranipour7 works
- Amir Keshvari7 works
- Mohammad Reza Keramati7 works
- Reza Alizadeh‐Navaei6 works
- Monireh Sadat Seyyedsalehi6 works
Most cited
- Cancer Research Center and registry
- Golestan Cohort Study (oesophageal cancer)
- Breast and GI oncology
- Oncology training
Similar pages
- InstitutionInstitut Salah Azaïez
Shares Cancer registries and population surveillance, Global oncology and access in low- and middle-income countries, International Agency for Research on Cancer (IARC / WHO), HR-positive / HER2-negative breast cancer.
- InstitutionDharmais National Cancer Center
Shares Cancer registries and population surveillance, Global oncology and access in low- and middle-income countries, International Agency for Research on Cancer (IARC / WHO), HR-positive / HER2-negative breast cancer.
- InstitutionInstituto Nacional de Cancerología (Colombia)
Shares Cancer registries and population surveillance, Global oncology and access in low- and middle-income countries, International Agency for Research on Cancer (IARC / WHO), Gastric & gastro-oesophageal junction cancer.
- Key paperParkin 2005: Global cancer statistics, 2002
Shares Cancer registries and population surveillance, International Agency for Research on Cancer (IARC / WHO), HR-positive / HER2-negative breast cancer, Colorectal cancer.
- InstitutionHo Chi Minh City Oncology Hospital
Shares Cancer registries and population surveillance, Global oncology and access in low- and middle-income countries, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- InstitutionCancer Institute (WIA), Adyar
Shares Cancer registries and population surveillance, Global oncology and access in low- and middle-income countries, International Agency for Research on Cancer (IARC / WHO), HR-positive / HER2-negative breast cancer.
- InstitutionInstituto Nacional de Enfermedades Neoplásicas
Shares Cancer registries and population surveillance, Global oncology and access in low- and middle-income countries, Gastric & gastro-oesophageal junction cancer, HR-positive / HER2-negative breast cancer.
- InstitutionInstituto Nacional de Cancerología (Mexico)
Shares Cancer registries and population surveillance, Global oncology and access in low- and middle-income countries, Gastric & gastro-oesophageal junction cancer, HR-positive / HER2-negative breast cancer.